CytoDyn Business Summary

CytoDyn Inc. is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, private placements, and debt financing, as it has yet to achieve commercial-stage product sales. The company’s business model is centered on the clinical development and eventual commercialization of leronlimab (PRO 140), a humanized monoclonal antibody targeting the CCR5 receptor. Its primary business segments are divided into three high-priority therapeutic areas: HIV (treatment-experienced and prevention), oncology (specifically metastatic triple-negative breast cancer and colorectal cancer), and inflammatory/autoimmune diseases. In the competitive landscape, CytoDyn contends with GeoVax Labs, Inovio Pharmaceuticals, and Dynavax Technologies, positioning itself as a specialized pioneer in CCR5 antagonism with a focus on converting "cold" tumors to "hot" through immune system modulation. Originally incorporated in 2002, CytoDyn is currently led by Chief Executive Officer Dr. Jacob Lalezari, a prominent clinical researcher with over 30 years of experience who previously served as the company’s Chief Medical Officer and CEO of Quest Clinical Research. The executive team includes Chief Financial Officer Robert E. Hoffman, who brings a pedigree from Arena Pharmaceuticals and AnaptysBio, and Dr. Max Lataillade, Senior Vice President and Head of Clinical Development, formerly a high-level R&D executive at ViiV Healthcare and Bristol-Myers Squibb. The Board of Directors is chaired by Tanya Durkee Urbach, a veteran in securities law and corporate governance. Notable financial backing has recently been secured through Yorkville Advisors Global LP, alongside support from activist retail investor groups and anonymous benefactors funding the company’s Expanded Access Programs.